No Prescription |
 |
 | ||
|
SEROFLO MULTIHALER ACCUHALER Advair Diskus |
|
| ||
No Prescription » Prescription Drugs 14 » SEROFLO MULTIHALER ACCUHALER Advair Diskus The combination of fluticasone and salmeterol is used to prevent wheezing shortness of breath and breathing difficulties caused by asthma and chronic obstructive pulmonary disease (COPD; a group of lung diseases that includes chronic bronchitis and emphysema). Fluticasone is in a class of medications called steroids. It works by reducing swelling in the airways. Salmeterol is in a class of medications called long-acting beta-agonists (LABAs). It works by relaxing and opening air passages in the lungs making it easier to breathe.The combination of fluticasone and salmeterol comes as a powder to inhale by mouth using a specially designed inhaler. It is usually used twice a day in the morning and evening about 12 hours apart. Use fluticasone and salmeterol at around the same times every day. Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any part you do not understand. Use fluticasone and salmeterol exactly as directed. Do not use more or less of it or use it more often than prescribed by your doctor. Buy SEROFLO MULTIHALER ACCUHALER Advair Diskus and other Prescription Drugs 14 products online at Medstore. Buy Online at Medstore - Click Here!
About SEROFLO MULTIHALER ACCUHALER Advair Diskus: Product Type: Prescription Drugs 14 SEROFLO -MULTIHALER (ACCUHALER) ( Advair Diskus Generic Salmeterol & Fluticasone ) SEROFLO -MULTIHALER (ACCUHALER Advair Diskus Generic Salmeterol & Fluticasone) ACCUHALER Advair Diskus Generic Salmeterol & Fluticasone 50/100mcg ACCUHALER Advair Diskus Generic Salmeterol & Fluticasone SEROFLO -MULTIHALER
View more Prescription Drugs 14 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
